Table 1.
Entry | Precursor Ion m/z | Extract | Identification | Elem. Comp. | Diff ppm | Comp. Type | Ref. |
---|---|---|---|---|---|---|---|
Extract analysis in positive mode ESI(+) | |||||||
1 | 191.1171 | RI24 | N-Methyl-5-hydroxytryptamine | C11H14N2O | 7.00 | Alkaloid | [40,41,42,43] |
2 | 391.2497 | RI23 | Sarmentogenin | C23H34O5 | 3.20 | Steroid | [44] |
3 | 399.2189 | RI18 | (5β,12β)-12,14-Dihydroxy-11-oxobufa-3,20,22-trienolide | C24H30O5 | 4.39 | Steroid | [45,46] |
399.2182 | RI23 | 2.63 | |||||
4 | 401.2306 | RI18 | 14,15-Epoxy-3,5-dihydroxybufa-20,22-dienolide (marinobufagin) | C24H32O5 | 5.48 | Steroid | [25,31,47,48] |
401.2318 | RI23 | 2.50 | |||||
5 | 403.2446 | RI23 | (3β,5β,16β)-3,5,16-Trihydroxy-bufa-14,20,22-dienolide (Bufogenin B) | C24H34O5 | 9.55 | Steroid | [49,50] |
6 | 435.2356 | RI19 | 11α,19-Di-hydroxy-telocinobufagin | C24H34O7 | 6.15 | Steroid | [46,51,52] |
433.2266 | RI24 | 9.17 | |||||
7 | 440.2167 | RI23 | Argentinogenin | C26H31O6 | 7.24 | Steroid | [44,53] |
8 | 445.2609 | RI18 | Bufotalin | C26H36O6 | 4.24 | Steroid | [35,44,54,55,56,57] |
9 | 458.2310 | RI23 | 19-Oxo-cinobufagin | C26H32O7 | 1.19 | Steroid | [36,44] |
10 | 461.2481 | RI24 | Monohydroxylbufotalin | C26H36O7 | 8.73 | Steroid | [6] |
11 | 531.2983 | RI23 | 3α,12β,25,26-Tetrahydroxy-7-oxo-5β-cholestane-26-O-sulfate | C27H46O8S | 1.63 | Steroid | [44] |
12 | 599.3231 | RI23 | Cinobufagin-3-hemisuberate | C34H46O9 | 1.82 | Steroid | [58] |
Extract analysis in negative mode ESI(−) | |||||||
13 | 433.2266 | RI24 | 11α,19-Di-hydroxy-telocinobufagin (Marinosin) | C24H34O7 | 9.17 | Steroid | [46,52,53] |
14 | 431.2116 | RI19 | Marinoic acid (3β-hydroxy-11,12-seco-5β,14β-bufa-20,22-dienolide-11,14-olide-12-oic acid) | C24H30O7 | 3.43 | Steroid | [59,60] |
Comp. type–component type (broad classification). Elem. comp.—elemental composition. RI–Rhinella icterica.